Trial reportBulletin of the World Health Organization2019
Provider and household costs of
Trial report in Bulletin of the World Health Organization, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- The economic burden of malaria in Africa: a systematic review of cost of illness studies.Malaria journal · 2025Pooled it
- The economic burden of malaria: a systematic review.Malaria journal · 2022Pooled it
- The household economic burden of human-only and zoonotic malaria, compared to other causes of acute febrile illness in Indonesia.BMJ global health · 2026Article
- Perceptions of shorter radical cure Plasmodium vivax treatment regimens and their implementation: a qualitative study among stakeholders in Cambodia.Malaria journal · 2025Article
- Economic burden of malaria on developing countries: A mini review.Parasite epidemiology and control · 2025Review
- Malaria morbidity, mortality and associated costs in Indonesia: analysis of the National Health Insurance claim dataset.BMJ global health · 2025Article
- Article
- Perspectives of healthcare professionals on training for quantitative G6PD testing during implementation of tafenoquine in Brazil (QualiTRuST Study).PLoS neglected tropical diseases · 2024Article
- The economic cost of malaria in Brazil from the perspective of the public health system.PLOS global public health · 2024Article
- Occupational exposure to malaria, leishmaniasis and arbovirus vectors in endemic regions: A systematic review.Current research in parasitology & vector-borne diseases · 2024Review
- A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria.Pathogens (Basel, Switzerland) · 2023Review
- Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.Scientific reports · 2021Article
- Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.PLoS medicine · 2021Article
- Cost-Effectiveness Analysis of Sex-StratifiedThe American journal of tropical medicine and hygiene · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 6 countries.
Funding
Abstract
objectiveTo determine household and health-care provider costs associated with
methodsWe collected cost data alongside three multicentre clinical trials of
findingsThe mean total household costs ranged from 8.7 United States dollars (US$; standard deviation, SD: 4.3) in Afghanistan to US$ 254.7 (SD: 148.4) in Colombia. Across all countries, productivity losses were the largest household cost component, resulting in mean indirect costs ranging from US$ 5.3 (SD: 3.0) to US$ 220.8 (SD: 158.40). The range of health-care provider costs for routine care was US$ 3.6-6.6. The cost of administering a glucose-6-phosphate-dehydrogenase rapid diagnostic test, ranged from US$ 0.9 to 13.5, consistently lower than the costs of the widely-used fluorescent spot test (US$ 6.3 to 17.4).
conclusionAn episode of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.